New study checks safety of injectable remsima for arthritis and psoriasis

NCT ID NCT05866614

Ongoing Disease control Sponsor: Celltrion Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing about 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who are taking Remsima (a biologic drug) either as a shot under the skin or through an IV. The goal is to track any serious side effects over time. Researchers want to see if the subcutaneous form is as safe as the IV form in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Remsima (infliximab) given as a subcutaneous injection or intravenous infusion
What this could lead to: If successful, this study could confirm that Remsima SC is a safe and convenient option for managing these chronic inflammatory conditions.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors, and rare side effects may not be detected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis psoriasis psoriatic arthritis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS PSORIASIS PSORIATIC ARTHRITIS RHEUMATOID ARTHRITIS

Contacts and locations

Locations

CHU Purpan Hôpital Pierre Paul Riquet

Toulouse, France, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.